Please wait while the formulary information is being retrieved.
EGRIFTA (TESAMORELIN ACETATE)
- Lipodystrophy associated with HIV
1 mg subcutaneous solution
- Inject 2 mg by subcutaneous route once daily
1 mg subcutaneous solution
- Inject 2 mg by subcutaneous route once daily
Lipodystrophy associated with HIV
- Inject 2 mg by subcutaneous route once daily
- None
Contraindicated
- None
Severe
Moderate
- None
- Hypothalamic-pituitary insufficiency
- Lactating mother
- Malignancy
- Pituitary insufficiency
- Pregnancy
- Radiation therapy of cranium
- Transsphenoidal hypophysectomy
Contraindicated
- None
Severe
Moderate
- Acute respiratory insufficiency
- Diabetes mellitus
- Edema
EGRIFTA (TESAMORELIN ACETATE)
- Lipodystrophy associated with HIV
- None
- Arthralgias
- Body fluid retention
- Hyperglycemia
- Injection site sequelae
- Myalgias
- Peripheral edema
More Frequent
Severe
Less Severe
- None
- Abdominal pain with cramps
- Carpal tunnel syndrome
- Depression
- Dyspepsia
- Flushing
- Hypertension
- Hypesthesia
- Insomnia
- Limb pain
- Nausea
- Night sweats
- Palpitations
- Paresthesia
- Urticaria
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Tesamorelin
No safety and efficacy. Risk of growth acceleration with open epiphyses.
- 1 Day – 18 Years
- No safety and efficacy. Risk of growth acceleration with open epiphyses.
Tesamorelin
- Severity Level:
X
- Additional Notes: Rat studies demonstrated hydrocephaly in offspring.
Contraindicated
Tesamorelin
Cdc does not recommend breastfeeding in hiv-positive women
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Cdc does not recommend breastfeeding in hiv-positive women |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Lipodystrophy associated with HIV | |
| E88.1 | Lipodystrophy, not elsewhere classified |
| 0-9 | A-Z |
|---|---|
| E88.1 | Lipodystrophy, not elsewhere classified |
Formulary Reference Tool